Enterolactone alters FAK-Src signaling and suppresses migration and invasion of lung cancer cell lines by unknown
RESEARCH ARTICLE Open Access
Enterolactone alters FAK-Src signaling and
suppresses migration and invasion of lung
cancer cell lines
Shireen Chikara1, Kaitlin Lindsey1, Pawel Borowicz1,3, Melpo Christofidou-Solomidou2 and Katie M. Reindl1*
Abstract
Background: Systemic toxicity of chemotherapeutic agents and the challenges associated with targeting
metastatic tumors are limiting factors for current lung cancer therapeutic approaches. To address these issues,
plant-derived bioactive components have been investigated for their anti-cancer properties because many of these
agents are non-toxic to healthy tissues. Enterolactone (EL) is a flaxseed-derived mammalian lignan that has
demonstrated anti-migratory properties for various cancers, but EL has not been investigated in the context of lung
cancer, and its anticancer mechanisms are ill-defined. We hypothesized that EL could inhibit lung cancer cell
motility by affecting the FAK-Src signaling pathway.
Methods: Non-toxic concentrations of EL were identified for A549 and H460 human lung cancer cells by
conducting 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Dephenyltetrazolium Bromide (MTT) assays. The anti-migratory and
anti-invasive potential of EL for lung cancer cell lines was determined by scratch wound healing and Matrigel®
invasion assays. Changes in filamentous actin (F-actin) fiber density and length in EL-treated cells were determined
using phalloidin-conjugated rhodamine dye and fluorescent microscopy. Vinculin expression in focal adhesions
upon EL treatment was determined by immunocytochemistry. Gene and protein expression levels of FAK-Src
signaling molecules in EL-treated lung cancer cells were determined using PCR arrays, qRT-PCR, and western
blotting.
Results: Non-toxic concentrations of EL inhibited lung cancer cell migration and invasion in a concentration- and
time-dependent manner. EL treatment reduced the density and number of F-actin fibers in lung cancer cell lines,
and reduced the number and size of focal adhesions. EL decreased phosphorylation of FAK and its downstream
targets, Src, paxillin, and decreased mRNA expression of cell motility-related genes, RhoA, Rac1, and Cdc42 in lung
cancer cells.
Conclusions: Our data suggest that EL suppresses lung cancer cell motility and invasion by altering FAK activity
and subsequent activation of downstream proteins needed for focal adhesion formation and cytoskeletal
rearrangement. Therefore, administration of EL may serve as a safe and complementary approach for inhibiting
lung tumor cell motility, invasion, and metastasis.
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Background
Enterolactone (EL) is a mammalian lignan derived from
the plant lignan secoisolariciresinol diglucoside (SDG)
that shows anti-migratory effects for breast, colon, and
prostate cancer cells with limited or no toxicity to
healthy cells [1–6]. EL suppressed adhesion, motility,
and invasion of breast cancer cells by remodeling the
actin cytoskeleton, downregulated gene expression of
matrix metalloproteinases (MMP-2, −9, and −14), and
inhibited FAK signaling [4, 5]. However, it is not clear
what effect EL has on lung cancer cell motility. Further,
the anti-cancer mechanisms for EL have not been clearly
established for lung cancer.
Support for the use of lignans such as SDG or EL in
lung cancer therapy comes from research showing their
protective effects for healthy lung tissues in lung injury
models. SDG reduced murine lung inflammation and oxi-
dative damage inflicted by radiation, a standard treatment
for metastatic lung cancer [7–10]. Given the protective ef-
fects of lignans for healthy lung tissue, and their anti-
migratory effects for other cancer types, we hypothesized
that EL would inhibit lung cancer cell migration.
Focal adhesion kinase (FAK) and steroid receptor co-
activator (c-Src) are signaling proteins that regulate cyto-
skeletal dynamics and cell motility by influencing actin
polymerization and focal adhesion turn-over [11, 12].
FAK and Src expression are elevated in non-small cell
lung cancer (NSCLC) tissues as compared to normal
lung tissue, and positively correlate with advanced stages
of disease [13–15]. Preclinical studies have shown that
FAK and Src inhibitors effectively suppress lung cancer
metastases; however, these agents induce cytotoxicity in
healthy tissues [16, 17]. Therefore, there is a need for
less toxic agents that target FAK-Src signaling and in-
hibit lung cancer cell motility.
The objective for this research was to identify EL as a
less toxic agent to inhibit lung cancer cell motility, and
to determine its anti-migratory mechanisms by focusing
on FAK-Src signaling and down-stream effects. Our central
hypothesis was that EL inhibits lung cancer cell motility by
altering focal adhesion formation and F-actin structure by
decreasing FAK-Src signaling. To address this hypothesis,
we investigated the anti-migratory and anti-invasive effects
of EL on NSCLC cells (A549 and H460), and determined
the impact on focal adhesion formation, actin filaments,
and the expression of mRNA and proteins associated with
cell motility. Our findings suggest that EL or its parent lig-
nan compound SDG could be used to inhibit NSCLC cell
motility by influencing FAK-Src signaling.
Methods
Materials
Purified EL (99.2% pure) was purchased from Chroma-
Dex, Inc (Santa Ana, CA). 3-(4, 5-Dimethylthiazol-2-yl)-
2, 5-Dephenyltetrazolium Bromide (MTT) was obtained
from AbD Serotech (Raleigh, NC). Matrigel® invasion
chambers with 8 μm pore size inserts were obtained
from BD Biosciences (Bedford, MA). Crystal violet was
obtained from Alfa Aesar (Ward Hill, MA). Rhodamine
phalloidin was purchased from Thermo Fisher Scientific
(Waltham, MA). Antibodies for p-FAKTyr397, t-FAK, p-
paxillinTyr118, t-paxillin, p-Src Tyr416, p-Src
Tyr527
, t-Src,
RhoA, p-Rac/Cdc42, t-Rac/Cdc42, GAPDH, and anti-
rabbit HRP-conjugated secondary antibody were pur-
chased from Cell Signaling Technology (Danvers, MA).
Antibody for vinculin was purchased from EMD Millipore
(Billerica, MA). Ki-67 and anti-mouse Alexa 633
fluorophore-conjugated antibodies were purchased from
Abcam (Cambridge, MA). DAPI was obtained from
Biotium (Fremont, CA). Coverslips were obtained
from Carl Zeiss (Ontario, Canada).
Cell culture and drug treatment
The human NSCLC cell lines A549 and H460 were pur-
chased from ATCC (Manassas, VA). Cells were main-
tained in RPMI-1640 medium (Sigma Aldrich; St. Louis,
MO), with 10% (v/v) fetal bovine serum (FBS; Atlanta
Biologicals; Flowery Branch, GA) and 1% penicillin/
streptomycin (Thermo Fisher Scientific). The cell lines
were incubated at 37 °C in a humidified atmosphere of
95% air and 5% carbon dioxide. They were sub-cultured
by enzymatic digestion with 0.25% trypsin/1mM EDTA
solution (Hyclone; Logan, UT) when they reached ap-
proximately 70% confluency.
EL was dissolved in 100% dimethysulfoxide (DMSO;
Corning Cellgro®; Corning, NY) at a stock solution con-
centration of 200 mM. The stock solution was freshly di-
luted in PBS (pH 7.2) to desired concentrations for every
experiment. The vehicle control was 0.2% DMSO.
MTT assay
The effect of EL on the viability of A549 and H460 cells
lines was studied using the MTT assay. Briefly, 3000
cells/well were plated in a 96-well plate. After 24 h of in-
cubation, medium was removed and the cells were
washed with PBS. Fresh RPMI-1640 medium was added,
and the cells were treated with vehicle (DMSO) or vari-
ous concentrations of EL (0, 10, 25, 50, 75, and 100 μM)
for 24 and 48 h. Next, 10 μl MTT (0.5 mg/ml) was
added to each well, and the plate was incubated for 4 h
at 37 °C. Later, the medium was removed and the cells
were washed with PBS. The resulting formazan crystals
were dissolved in 100 μl of DMSO, and the absorbance
reading of each well was taken at 570 nm using a plate
reader (Microplate XMark™ spectrophotometer; Bio-Rad;
Hercules, CA). The percentage of cell survival was
calculated using the background-corrected absorbance
as shown in the following formula:
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Cell survival %ð Þ ¼ Absorbance Treatment=AbsorbanceControlð Þ
X 100
The data shown represent the mean and standard de-
viation from 8 replicate wells for each treatment for 3
independent experiments.
Migration assay
The ability of EL to inhibit migration of A549 and H460
cells was investigated using a wound healing assay. Cells
were seeded into 6-well dishes and grown to 80–90%
confluency. A sterilized 10 μl pipette tip was used to
generate a wound across the cell monolayer. The cellular
debris was washed with PBS, serum-free RPMI-1640
medium was added to each well, and the cells were
treated with fresh vehicle (DMSO) or EL (10, 50, and
100 μM) every 24 h. The open gap was photographed
microscopically after 24 and 48 h. The migration ability
of the cells was determined by measuring the width of
the monolayer wound for three fields per treatments at
24 and 48 h after scraping, and the migration index was
calculated using the following formula, where ‘T’ stands
for time (24 or 48 h).
Migration index ¼ }0} h scratch width – }T} h scratch widthÞ




The data shown represent the mean and standard de-
viation of 3 independent experiments.
Ki-67 Immunocytochemistry
To verify that EL inhibited migration of lung cancer cells
independent of its effects on cell proliferation, we
stained lung cancer cells with the proliferation marker
Ki-67. Cells were seeded into 6-well dishes, and after
they reached 80–90% confluency, a wound across the
cell monolayer was created with a sterilized 10 μl pip-
ette. After removal of cellular debris, serum-free RPMI-
1640 medium was added, and the cells were treated with
vehicle (DMSO) or EL (100 μM) for 24 and 48 h, with
fresh treatment added after 24 h. The cells were fixed
with 4% formaldehyde solution and permeabilized with
0.1% Triton-X 100. Next, the cells were washed with 1x
TBS-tween (0.1%) and blocked with 10% normal goat
serum (NGS) for 1 h, washed with 1x TBS-tween (0.1%),
and incubated with anti-Ki-67 primary antibody for 3 h.
The cells were washed again with 1x TBS-tween (0.1%)
and incubated with Alexa Fluor 633 anti-rabbit second-
ary antibody for 1 h. After DAPI counterstaining, the
number of Ki-67 positive cells across the wound were
examined using a Zeiss Axio Observer Z1 inverted
microscope with LSM700 laser scanning unit and 20x
0.8 objective (Zeiss, Thornwood, NY). The cell prolifera-
tion ratio was calculated using ImagePro Premier soft-
ware (Media Cybernetics, Silver Spring, MD, USA). The
data shown represent the mean and standard deviation
of 2 random fields per sample for three independent ex-
periments for each cell line.
Invasion assay
The ability of EL to inhibit invasion of A549 and H460
cells was investigated using Matrigel® invasion chambers
consisting of invasion inserts (8 μm pore size). A549 and
H460 cells (5 x 106 cells/well), suspended in serum-free
RPMI-1640, were placed in the upper chamber of the
transwell inserts and incubated with vehicle (DMSO) or
EL (100 μM). RPMI-1640 medium supplemented with
50% FBS was added to the lower chamber. The plates
were incubated in a humidified atmosphere with 95 air
and 5% CO2 at 37 °C for 24 and 48 h. Fresh serum-free
medium along with EL treatment was added in the
upper chamber after 24 h. The non-invasive cells,
present on the inside of the upper chamber, were re-
moved by wiping with a cotton swab dipped in PBS, and
invasive cells, present on the underside of the upper
chamber, were fixed with 4% formaldehyde in PBS and
later stained with 2% crystal violet. Invasive cells were
then photographed under a light microscope at 200X.
Cytoskeleton organization analysis
Actin cytoskeleton staining was carried out with phal-
loidin conjugated-rhodamine dye. A549 and H460 cells,
grown on glass coverslips, were treated with vehicle
(DMSO) or EL (10, 50, and 100 μM) for 24 h. After
treatment, the cells were washed twice with PBS and
fixed with 4% formaldehyde in PBS for 15 min at room
temperature. The cells were washed twice with PBS and
permeabilized with 0.1% Triton-X 100 for 5 min. Follow-
ing permeabilization, the cells were washed with PBS
and blocked with 1% BSA for 1 h. The cells were then
incubated with phalloidin conjugated-rhodamine for 20
min at 37 °C. After incubation, the cells were washed
with PBS and incubated with DAPI for 3–4 min to label
nuclei. Finally, coverslips were mounted onto slides with
the help of aqua-poly-mount mounting medium. Con-
focal images were acquired using an inverted fluores-
cence microscope with 40X oil immersion lens. At least
5 independent random fields per sample were captured
from three independent experiments. The acquired im-
ages were converted into binary images for quantifica-
tion of the density and average length of F-actin fibers
using Image Pro Premier software (9.0).
Immunofluorescence and confocal microscopy
To visualize focal adhesions, A549 and H460 cells grown
on fibronectin-coated coverslips were treated with ve-
hicle (DMSO) or EL (100 μM) for 24 h. After treatment,
the cells were washed with PBS, fixed with 4% formalde-
hyde solution for 15 min at room temperature, and
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permeabilized with 0.1% Triton-X 100 for 10 min. Next,
the cells were washed with 1x TBS-tween (0.1%),blocked
with 10% NGS for 1 h, washed with 1x TBS-tween
(0.1%), and incubated with anti-vinculin primary antibody
for 3 h. The cells were washed again with 1x TBS-tween
(0.1%) and incubated with Alexa Fluor 633 anti-mouse
secondary antibody for 1 h. These cells were then incu-
bated with DAPI for 3–4 min to label nuclei. The cover-
slips were then mounted onto slides with the help of
aqua-poly-mount mounting medium and examined using
Zeiss Axio Observer Z1 inverted microscope with
LSM700 laser scanning unit and 40x 1.3NA oil objective
(Zeiss, Thornwood, NY). The number and size of focal ad-
hesions per cell were examined analyzed using the Image-
Pro Premier software (Media Cybernetics, Silver Spring,
MD, USA) in 10 individual cells for each treatment for
three independent experiments.
Microarray analysis for cell-motility related genes
Total RNA was isolated from untreated control and EL-
treated (100 μM; 24 h) A549 cells (1 X 106 cells) using
the Fisher SurePrep kit as per the manufacturer’s in-
structions. cDNA was synthesized using 100 ng of total
RNA and the qScript cDNA synthesis kit (Quanta Bio-
sciences; Beverly, MD). Subsequently, qPCR was per-
formed using PerfeCTa SYBR Green FastMix (Quanta
Biosciences) and the PrimePCRTM Pathway Plates (Bio-
Rad; Hercules, CA) to investigate the effects of EL on
cell motility-related genes regulating FAK and platelet-
derived growth factor (PDGF) signaling. The cycling pa-
rameters were: 95 °C for 10 min followed by 40 cycles at
95 °C for 30 s and 60 °C for 1 min, and a dissociation
program that included 95 °C for 1 min, 55 °C for 30 s,
and 95 °C for 30 s ramping up at 0.2 °C/s. One distinct
peak was observed for each primer set, suggesting target
specificity. Duplicate wells were run for each experi-
ment, and the experiment was performed in duplicate.
The relative change in gene expression was calculated
using 2-ΔΔCt method using housekeeping genes TBP,
GAPDH, and HPRT1 as internal controls.
Quantitative reverse transcriptase polymerase chain
reaction (qRT-PCR)
Total RNA was isolated from untreated control and EL-
treated (100 μM; 24 h) A549 and H460 cells (1 X 106
cells) using the Fisher SurePrep Kit (Waltham, MA) as
per the manufacturer’s instructions. cDNA was synthe-
sized using 100 ng of total RNA and the qScript cDNA
synthesis kit (Quanta Biosciences). Primers for RhoA, Rac,
Cdc42, and 18S rRNA were designed using Primer Ex-
press software (version 2.0, Applied Biosystems; Foster
City, CA), and were synthesized by Integrated DNA
Technologies (Coralville, IA). The primer sequences
were as follows: RhoA Forward GAGTTGGCTTTGTGG
GACACA, RhoA Reverse ACTATCAGGGCTGTCGAT
GGA, Rac1 Forward GCTTATGGGATACAGCTGGAC
AA, Rac1 Reverse AGGACTCACAAGGGAAAAGCAA,
Cdc42 Forward GATTACGACCGCTGAGTTATCCA,
Cdc42 Reverse CAGGCACCCACTTTTCTTTCAC.
Steady-state mRNA levels for the cell cycle-related
genes were evaluated by qPCR using PerfeCTa SYBR
Green FastMix (Quanta Biosciences). The cycling pa-
rameters were: 95 °C for 10 min followed by 40 cycles at
95 °C for 30 s and 60 °C for 1 min, and a dissociation
program that included 95 °C for 1 min, 55 °C for 30 s,
and 95 °C for 30 s ramping up at 0.2 °C/s. One distinct
peak was observed for each primer set, suggesting target
specificity. Duplicate wells were run for each experiment
and the experiment was performed in triplicate. The
relative change in gene expression was calculated using
2-ΔΔCt method using the housekeeping gene 18S rRNA
as an internal control.
Western blotting
A549 and H460 lung cancer cells (3 x 105 cells/well)
were seeded in a 24-well plate. After 24 h of incubation,
the cells were treated with vehicle (DMSO) or EL (100
μM) for 0, 1, 3, 6, 12, and 24 h. The cells were then har-
vested by trypsinization, centrifuged at 300 x g for 10
min. The resulting cell pellet was then lysed by brief
sonication in 100 μl of SDS lysis buffer (Cell Signaling
Technologies) containing protease and phosphatase in-
hibitors (Roche; Indianapolis, IN) to dissociate cell
membranes. Fifty micrograms of total protein isolated
from these cells were electrophoresed on 7.5% SDS-
polyacrylamide gels at 100 V for 1 h. Proteins were then
transferred to nitrocellulose membranes at 100 V at 4 °C
for 70 min. The blots were then probed overnight at 4 °C
with primary antibodies (1:1000) for p-FAKTyr397, t-FAK,
p-paxillinTyr118, t-paxillin, p-SrcTyr416, p-Src
Tyr527
, t-Src,
RhoA, p-Rac/Cdc42, t-Rac/Cdc42, and GAPDH. The next
day, the blots were rinsed with 1X TBS-tween (0.1%) and
probed with anti-rabbit HRP-conjugated secondary anti-
bodies (1:5000) for 1 h at room temperature. The western
blots were analyzed using SuperSignal West Pico Chemi-
luminescent Substrate (Thermo Fisher Scientific) and the
images were captured using the MultiImage™ Light Cabi-
net (Alpha Innotech; San Leandro, CA). Western blotting
was performed in triplicate. The densitometry results were
obtained using ImageJ software.
Statistical analyses
Data are presented as means ± standard deviation for
at least 3 independent experiments. The statistical
significance of difference between the control and
treatment groups was determined by paired t-test or
two-way ANOVA. p ≤ 0.05 were considered statisti-
cally significant.
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Results
EL has minimal effect on growth of lung cancer cells at
24 and 48 h
To investigate the effect the EL on lung cancer cell via-
bility, A549 and H460 cells were treated with different
concentrations of EL (0–100 μM) for 24 and 48 h. Via-
bility was assessed using the MTT assay. The results
show that EL had no effect on the proliferation of A549
and H460 cells at 24 h (Fig. 1a and b). A minimal
concentration-dependent decrease in cell proliferation
was observed in response to EL-treatment at 48 h, with
a 20% decrease observed in A549 and 15% decrease in
H460 treated with the highest concentration (100 μM)
of EL (Fig. 1a and b).
EL inhibits in vitro migration of lung cancer cells
A scratch wound healing assay was used to examine the
anti-migratory effects of EL in A549 and H460 cells.
Cells were either treated with vehicle control (DMSO)
or EL (10, 50, 100 μM) for 24 and 48 h. Control A549
and H460 cells demonstrated their migration potential
by resulting in 55 and 40% wound repair after 24 h, and
100 and 90% wound repair after 48 h, respectively
(Fig. 2). On the other hand, EL treatment (10, 50, and
100 μM) of A549 cells suppressed wound healing in a
concentration- and time- dependent manner, with 42,
22, and 23% wound closure after 24 h, respectively
(Fig. 2a and b), and 88, 70, and 56% wound closure after
48 h, respectively (Fig. 2a and b). For H460 cells, 10, 50,
and 100 μM EL treatment resulted in 35, 28, and 17%
wound closure after 24 h (Fig. 2c and d), respectively,
and 39, 39, and 36% of wound closure after 48 h (Fig. 2c
and d), respectively.
Ki-67 immunocytochemistry was performed to rule
out the possibility that EL inhibited cell proliferation
which resulted in reduced cell migration. After creating
a scratch wound, A549 and H460 cells were either
treated with the vehicle control (DMSO) or EL (100
μM) for 24 and 48 h. The cell proliferation rate, qualita-
tively measured by the number of Ki-67 positive cells
near the wound edge, was similar in control and EL-
treated A549 and H460 cells (Fig. 2e and g). In A549
cells, on an average, there were 7.9% Ki-67 positive cells
in the control group and 8.4% in the treatment group
after 24 h, and 9.4 and 9.0%, respectively, after 48 h
(Fig. 2f ). Similarly, in H460, these numbers were 8.8 and
9.2% after 24 h, and 10.1 and 9.5% after 48 h (Fig. 2h).
These results suggest that the anti-migratory effects of
EL on lung cancer cells are independent of its effect on
cell proliferation.
EL inhibits in vitro invasion of lung cancer cells
The effect of EL treatment (100 μM) on cancer cell inva-
sion after 24 and 48 h was studied using Matrigel® inva-
sion chambers. As shown in Fig. 3a and c, compared to
the untreated control, the number of invading cells rep-
resented by crystal-violet stain was reduced remarkably
in a time-dependent manner in A549 and H460 cells.
The inhibitory effects of EL (100 μM) on cancer cell in-
vasion, as measured by the percentage of control, were
47 and 68% in A549 cells, and 20 and 37% in H460 cells,
after 24 and 48 h, respectively (Fig. 3b and d). These re-
sults suggest that EL inhibits the in vitro invasive poten-
tial of lung cancer cells.
EL affects the actin cytoskeleton in lung cancer cells
Given the importance of the cytoskeletal structure on
cell motility, the effect of EL treatment (100 μM; 24 h)
on the distribution of F-actin fibers was visualized with
the help of phalloidin-conjugated rhodamine dye. The
results from immunofluorescence microscopy indicate
that after 24 h, control A549 and H460 cells exhibited
dense F-actin fibers, while EL-treated cells showed a loss
of F-actin fibers (Fig. 4a and d). Further, long F-actin
Fig. 1 EL has minimal effects on lung cancer cell viability. Lung cancer cell lines a A549 and b H460 were treated with different concentrations of
EL (0, 10, 25, 50, 75, and 100 μM) for 24 and 48 h, and cell viability was measured using an MTT assay. The data represent the average ± standard
deviation of eight replicate wells for three independent experiment for each cell line. p≤ 0.05 was considered statistically significant when
compared with untreated control
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fibers running across the cell body were seen in control
cells, while branched and broken actin fibers were ob-
served in EL-treated cells (Fig. 4a and d). Compared to the
control, EL treatment resulted in a decrease in the per-
centage of polymerized F-actin fibers from 52.9 to 39.2%
in A549 cells and from 50.9 to 32.9% in H460 cells (Fig. 4b
and e). This difference was statistically significant in A549
cells (p ≤ 0.05). In addition, compared to the control, EL-
treatment decreased the average length of F-actin fibers
from 201.4 to 115.5 nm in A549 and 206.5 to 147.3 in
H460 cells, with a statistically significant difference ob-
served in A549 cells (p ≤ 0.05) (Fig. 4c and f). These
results suggest that EL inhibits lung cancer cell motility by
interfering with actin microfilament formation.
Fig. 2 EL impairs the in vitro migration potential of lung cancer cells independent of cell proliferation. a A549 and c H460 cells were grown to
90% confluency in cell culture dishes. A scratch/wound was made in each dish. The cells were then treated with 0, 10, 50, and 100 μM EL for 24
or 48 h. Images were taken at each time point for the respective control and treatment groups. The distance across the wound was measured for
three replicate experiments for b A549 and d H460 cells and quantified as the % migration index. Ki-67 staining and quantification of e and f
A549 and g and h H460 cells were performed to identify the % of Ki-67 positive cells near the wound. The data represent the average ± standard
deviation % migration index for three fields per treatments for three independent experiments. p≤ 0.05 was considered statistically significant
when compared with untreated control
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Fig. 3 EL suppresses in vitro invasive potential of lung cancer cells. a A549 and c H460 cells were placed in the upper chamber of the Matrigel
inserts (8 μm pore size) in serum-free RPMI-1640 medium, and then treated with 0 or 100 μM EL for 24 or 48 h. The number of invaded cells were
fixed with 4% formaldehyde and stained with 2% crystal violet. Invasive cells were then photographed under a light microscope at 200x. The
number of invasive b A549 and d H460 cells were counted for three replicate experiments and quantified. p ≤ 0.05 was considered statistically
significant when compared with untreated control
Fig. 4 EL effects cytoskeletal organization. a A549 and d H460 lung cancer cells grown on glass coverslips were treated with DMSO or EL
(100 μM) for 24 h. Immunocytochemistry was conducted using rhodamine-conjugated phalloidin to visualize F-actin fibers. Cells were imaged using
an inverted fluorescence microscope (blue fluorescence represents DAPI stained nuclei and red fluorescence indicates rhodamine-conjugated
phalloidin-stained F-actin filaments). The acquired images were converted into binary images for quantification on Image Pro Premier software (9.0).
The density of F-actin filaments was determined for both b A549 and e H460 cells treated with or without EL. The average length of the F-actin
filaments per cell was determined for c A549 and f H460 cells. p≤ 0.05 was considered statistically significant when compared with untreated control
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EL reduces the number and size of focal adhesions in
lung cancer cells
Focal adhesions provide a structural link between the
actin cytoskeleton and extracellular matrix (ECM).
Therefore, we investigated the effect of EL on focal ad-
hesion number and size in lung cancer cells. A549 and
H460 cells were seeded onto fibronectin-coated cover-
slips, and immunofluorescent staining for expression of
vinculin, a membrane-cytoskeletal protein present in
focal adhesion plaques, was performed. Control and EL-
treated (100 μM; 24 h) A549 and H460 cells displayed
prominent focal adhesions at their periphery (Fig. 5a and
d). However, EL-treatment caused a reduction in the
average number of focal adhesions per cell for both
A549 and H460 cells. In A549 cells, control cells exhib-
ited an average of 21.6 focal adhesions, while EL-treated
cells showed a statistically significant reduction in focal
adhesions with an average of only 12.5 focal adhesions
per cell (p ≤ 0.05) (Fig. 5b). Similarly, in H460 cells, the
control cells exhibited an average of 22.5 focal adhe-
sions, while EL-treated cells showed a reduction in focal
adhesion with an average of 13.1 focal adhesions per cell
(Fig. 5e). In addition, EL treatment affected the size of
focal adhesions in A549 and H460 cells. In A549 cells,
the average size of focal adhesions was 1.33 μm2/cell in
control cells and 1.22 μm2/cell in EL-treated cells
(Fig. 5c). Similarly, in H460 cells, the average size of
focal adhesions was 2.02 μm2/cell while EL-treated cells
showed a statistically significant decrease in the size of
focal adhesions with the average being 1.38 μm2/cell
(p ≤ 0.05) (Fig. 5f ).
EL influences the mRNA expression of cell motility-related
genes
We employed PrimePCR™ Pathway microarray plates to
investigate the effects of EL on the expression of genes
associated with FAK and PDGF signaling pathways. We
found that EL-treatment (100 μM; 24 h) led to differential
regulation of a number of genes in the two signaling path-
ways (Additional file 1: Table S1). Importantly, we ob-
served that RhoA, Rac1, and Cdc42 genes that overlapped
in the two signaling pathways, were consistently down-
regulated in response to EL-treatment. Further, an integrin
subunit alpha 2 (ITGA2) that helps anchor cells to the
ECM was significantly up-regulated. To validate the re-
sults obtained by microarray analysis, we performed RT-
qPCR. Compared to the control, EL-treatment (100 μM;
24 h) led to down-regulation of RhoA, Rac1, and Cdc42
mRNA expression in A549 and H460 cells (Fig. 6a and b).
The observed decrease in mRNA expression for all the
three genes was statistically significant in A549 cells, while
H460 cells showed a significant (p ≤ 0.05) decrease in
Rac1 and Cdc42 mRNA expression. These results suggest
that EL treatment alters the expression of key transcripts
associated with cell motility.
Fig. 5 EL reduces the number and size of focal adhesions in lung cancer cells. A549 and H460 lung cancer cells grown on glass coverslips were
treated with DMSO or EL (100 μM) for 24 h. Immunocytochemistry for vinculin expression and localization was performed for a A549 and d H460
cells. Cells were imaged using an inverted fluorescence microscope. Image Pro Premier software (9.0) was used to identify the number of focal
adhesions per cell for b A549 and e H460 cells. The focal adhesion size (μm2) per cell was also determined for c A549 and f H460 cells based on
pixel count
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EL modulates FAK-Src signaling in lung cancer cells
De-regulation of the FAK-Src signaling cascade mediates
cancer cell migration in lung cancer cells. Therefore, we
investigated the effect of EL treatment on the phosphoryl-
ation status of FAK and Src proteins. The western blot re-
sults show that 100 μM EL decreased phosphorylation of
FAK on Y397 (Fig. 7a-d). In addition, in A549 and H460
cell, 100 μM EL decreased phosphorylation of Src on its
kinase domain containing an auto-phosphorylation site
(Y416) that is necessary for its activation (Fig. 7a-d). Sim-
ultaneously, EL increased phosphorylation on the carboxyl
terminal domain of Src that contains a regulatory tyrosine
(Y527), that upon phosphorylation maintains Src in an in-
active conformation (Fig. 7a-d). These results suggest that
EL inhibits FAK-Src activation which could explain the
observed changes in cell migration and invasion in A549
and H460 lung cancer cells.
EL inhibits phosphorylation of paxillin and Rho proteins
in lung cancer cells
Paxillin is a major substrate of the FAK-Src complex and
plays an important role in cell migration and cytoskeletal
reorganization. Phosphorylated FAK initiates phosphor-
ylation of paxillin on Y118, a prerequisite for cell migra-
tion. Therefore, we investigated if inhibition of FAK-Src
signaling pathway by EL as seen in Fig. 7a-d was accom-
panied by inhibition in paxillin phosphorylation. EL-
treatment (100 μM) decreased phosphorylation status of
paxillin on the Y118 residue in A549 and H460 cells
(Fig. 7e-h).
RhoA, Rac1, and Cdc42 are critical proteins down-
stream of FAK-Src-paxillin signaling pathway and play
important roles in cell migration. Therefore, we next in-
vestigated if EL-mediated downregulation in mRNA ex-
pression of RhoA, Rac1, and Cdc42 co-related with a
decrease in their protein expression. As shown in
Fig. 7e-h, decreased RhoA protein levels were observed
in A549 and H460 cells after EL treatment (100 μM). EL
treatment (100 μM) resulted in a slight increase in
proteins levels of p-Rac/Cdc42 in A549 cells, and a de-
crease in p-Rac/Cdc42 protein levels in H460 (Fig. 7e-h).
These results suggest that EL may affect stress fiber for-
mation (a role of RhoA), but to a lesser degree filapodia
or lamellopodia formation (roles for Rac and Cdc42).
Discussion
Our data support the hypothesis that EL modulates lung
cancer cell motility by inhibiting FAK-Src signaling. In
this study, we observed that the anti-migration and inva-
sion effects of EL in lung cancer cells were not
dependent on its anti-proliferative effect. Here we have
shown evidence that EL, at non-toxic concentrations, in-
hibits A549 and H460 cell invasion and migration by: (i)
disrupting F-actin cytoskeleton dynamics, (ii) reducing
the number and size of focal adhesions, and (iii) inhibit-
ing the activation of the FAK-Src-paxillin signaling cas-
cade and expression of down-stream motility regulators.
These results are significant because inhibition of lung
cancer metastasis remains a therapeutic challenge. Nat-
ural products, such as EL, that show anti-migratory ef-
fects with limited or no toxicity to healthy tissues would
be valuable additions to lung cancer treatment regimens.
A number of studies have demonstrated the anti-
proliferative effects of EL in cancer cell lines. In PC-3
prostate cancer cells, EL (40 μM; 24 h) inhibited IGF-1-
induced cell proliferation by arresting cells at G0/G1-
phase of the cell cycle and EL (60 μM; 20 h) suppressed
migration [2]. Similarly, in MDA-MB-231 breast cancer
cells, EL (100 μM) suppressed migration at 24 h and
arrested cells at S-phase of the cell cycle after 48 h [5].
We have previously observed that EL (≥50 μM) inhibits
proliferation of lung cancer cells and induces G0/G1-
phase cell cycle arrest in lung cancer cells after 48 h
(under review). In this study, we observed that non-toxic
concentrations of EL (10, 50, and 100 μM) inhibited mo-
tility of lung cancer cells after only 24 h. Further, Ki-67
staining results indicate that EL-mediated inhibition of
migration was not influenced by inhibition of cell
Fig. 6 EL treatment of lung cancer cells results in decreased mRNA expression of Rho GTPases. a A549 and b H460 cells were treated with 0 or
100 μM EL for 24 h. Total RNA was extracted from the cells and subjected to qRT-PCR for RhoA, Rac1, and Cdc42. The experiments were conducted in
triplicate. The data were normalized to 18S rRNA expression and represent the average fold change in mRNA expression for EL-treated cells relative to
the control. p≤ 0.05 was considered statistically significant when compared with untreated control
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proliferation. Therefore, our data supports previous re-
search highlighting the cytostatic and anti-migratory po-
tentials of EL, and extends the research to lung cancer,
which has a high metastatic potential.
The majority of studies involving the anti-migration
and invasion potential of EL have been performed using
breast cancer cell lines, namely MDA-MB-231 cells
[1, 4, 5]. Studies have shown that EL inhibits breast
cancer cell adhesion to ECM proteins [1], and inhibits
breast cancer cell migration and invasion by reducing
MMP-2, −9, and −14 mRNA expression [4]. We did
not detect significant changes in MMP mRNA or
protein expression in A549 or H460 lung cancer cells
treated with EL (data not shown). A likely explanation
for differing molecular responses may stem from the
fact that EL is derived from a phytoestrogen known
as SDG, and may show varied effects on different
cancer cell types.
A recent study provided more mechanistic detail for
EL’s anti-migratory effects for breast cancer. This study
Fig. 7 EL treatment of lung cancer cells alters levels of FAK-Src signaling proteins. a-d A549 or e-h H460 cells were treated with 100 μM EL for 0,
1, 3, 6, 12, or 24 h. Western blotting was done to identify changes in total or phosphorylated levels of FAK, Src, paxillin, RhoA, and Rac/Cdc42
proteins. The blots represent one typical result from three independent experiments. Phosphorylated levels of proteins were normalized to
their respective total protein levels. Alternatively, GAPDH was used as a loading control. Densitometry was performed using ImageJ software.
p≤ 0.05 was considered statistically significant when compared with untreated control
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demonstrated that EL inhibited breast cancer cell migra-
tion and invasion by decreasing levels of phosphorylated
FAK at tyrosine 397 (Y397) and phosphorylated paxillin
[5]. Phosphorylation of FAK at Y397 is critical for its ac-
tivation and recruitment of Src [18]. Similarly, we found
that EL reduced FAK Y397 phosphorylation and de-
creased phosphorylated paxillin in lung cancer cell lines.
Further, we found EL elevated phospho-Src at Y527, and
reduced phospho-Src at Y416. Phosphorylation at Y527
maintains Src in an inactive conformation and inhibits
its recruitment to FAK, while phosphorylation at Y416
results in its activation [19, 20]. Deregulation of FAK-Src
signaling is seen in several tumor types [21–23]. Lung
tumors with elevated FAK and Src activity have in-
creased metastatic potential [14, 15]. Therefore, inhib-
ition of FAK-Src signaling by EL may reduce the
capacity of lung cancer cells to migrate.
Cell migration is primarily driven by: (i) polymerization
of F-actin, and formation of focal adhesion complexes at
the leading edge, and (ii) F-actin depolymerization, and
disassembly of focal adhesion complexes at the rear end
of the cell. The activated FAK-Src-paxillin complex
contributes to cell migration through the Rho family
of small GTPases, such as RhoA, Rac1, and Cdc42
[24]. RhoA affects cell-cell or cell-ECM interaction by
inducing cytoskeleton changes; Rac1 plays a role in
membrane ruffling by driving actin polymerization; and
Cdc42 is involved in the formation of filopodia through
initiating F-actin filament assembly. In this study, we have
shown that EL decreased the density of F-actin fiber and
disrupted the formation of long stress fiber that traverse
the cell body. This change in actin cytoskeleton leading
to reduced cell migration was associated with down-
regulation of RhoA, Rac1, and Cdc42 expression, which
might impair cell body contraction and retraction at
the rear end of the cell, and limit formation of protrusions
at the leading edge.
In addition to down-regulating Rho GTPases, we
found EL elevated ITGA2 mRNA expression in lung
cancer cells. Integrins are transmembrane proteins that
connect the extracellular matrix with the actin cytoskel-
eton. Loss of ITGA2 expression is frequently observed
in solid tumors, and the silencing of ITGA2 resulted in
enhanced breast cancer migration [25]. Therefore, EL-
induced ITGA2 expression may anchor lung cancer cells
to the matrix and prevent cell migration.
Conclusions
In summary, EL treatment inhibits lung cancer cell migra-
tion by altering F-actin dynamics, suppressing formation
of focal adhesion complexes, and activating FAK-Src
signaling. EL also alters the expression of a number of
regulators of the actin cytoskeleton and cell migration.
Additional studies are needed to identify how EL could be
used as a complementary approach to currently used che-
motherapies for lung cancer. Also, more studies designed
to investigate the mechanisms behind EL’s anti-cancer
effects are needed. Altogether, EL holds promise as an
adjuvant treatment to prevent tumor cell motility.
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